Tseng CH - This study was carried out to determine if metformin can reduce the risk of hepatocellular carcinoma (HCC). From Taiwan’s National Health Insurance database, type 2 diabetes patients newly diagnosed during 1999-2005 and with 2 or more prescriptions of antidiabetic drugs were enrolled. In total, 173,917 ever-users and 21,900 never-users of metformin were identified (unmatched cohort). Findings suggested an association of metformin with a reduced risk of HCC in a dose-response pattern. Data reported that metformin and aspirin or metformin and statin users were at the lowest risk.